Trials
July 3, 2024
Joshua M. Poulin, Gregory E. Bigford, Krista L. Lanctôt et al.
3 citations
Major depressive disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of life. Approximately one third of individuals with depression do not fully respond to treatments (e.g., conventional antidepressants, psychotherapy) and alternative strategies are needed. Recent early phase trials suggest psilocybin may be a safe and...
Cerebral Cortex
July 1, 2024
Yupeng Han, Lizhao Du, Qiyun Huang et al.
Meditation, mental training that aims to improve one's ability to regulate their cognition, has been widely applied in clinical medicine. However, the mechanism by which meditation affects brain activity is still unclear. To explore this question, electroencephalogram data were recorded in 20 long-term meditators and 20 nonmeditators during 2 high-level cognitive tasks (meditation and mental...
Schizophrenia Research
July 1, 2024
Vittorio Gallese, Martina Ardizzi, Francesca Ferroni
18 citations
Despite the historically consolidated psychopathological perspective, on the one hand, contemporary organicistic psychiatry often highlights abnormalities in neurotransmitter systems like dysregulation of dopamine transmission, neural circuitry, and genetic factors as key contributors to schizophrenia. Neuroscience, on the other, has so far almost entirely neglected the first-person...
Journal of Pakistan Psychiatric Society
June 30, 2024
Nauman Ashraf
1 citation
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religious ceremonies to facilitate spiritual experiences. Lysergic acid diethylamide (LSD) was used clinically from the 1950s until its ban in 1967. Recently, there has been a resurgence of interest in psychedelics for treating mental health disorders such...
Journal of Eating Disorders
June 12, 2024
Amanda Timek, Catherine Daniels-Brady, Stephen Ferrando
8 citations
Anorexia nervosa is a life-threatening psychiatric illness with a high mortality rate and limited treatment options. This illness is frequently comorbid with major depressive disorder, leading to additional obstacles in patient quality of life, and increasing the mortality rate further due to risk of suicide. Ketamine, a competitive N-methyl-D-aspartate receptor antagonist, has been shown to be...
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal
June 10, 2024
Linda Nguyen, Sona Regonda, Adam Gaisinsky
Introduction: Psilocybin is a naturally occurring tryptamine derivative psychedelic compound potently produced by fungi members of the genus Psilocybe. Previous literature has highlighted psilocybin as a serotonin 2A receptor agonist with striking effects on neural plasticity and cognition. Recent studies explore the usage of psilocybin in addressing addictive behaviours and substance abuse....
Frontiers in Psychiatry
June 10, 2024
Leehe Peled-Avron, Jacob S. Aday, Amilia Lydia Kalafateli et al.
2 citations
Editorial on the Research Topic Down the rabbit hole -the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions Psychedelic substances have demonstrated promising therapeutic effects across a wide range of mental health conditions including depression (1-13) anxiety disorders including generalized anxiety (14-16) and social...
Frontiers in Psychiatry
June 4, 2024
Julia Bornemann, James B. Close, Kirran Ahmad et al.
11 citations
Background Chronic pain is a leading cause of disability worldwide. Fibromyalgia is a particularly debilitating form of widespread chronic pain. Fibromyalgia remains poorly understood, and treatment options are limited or moderately effective at best. Here, we present a protocol for a mechanistic study investigating the effects of psychedelic-assisted-therapy in a fibromyalgia population. The...
Revista de Investigación Científica y Tecnológica
June 2, 2024
Ayahuasca, un té utilizado inicialmente por pueblos amerindios, con fines medicinales, religiosos y sacramentales, y luego se difundió en muchas partes del mundo en contextos urbanos, que, además de su uso religioso y espiritual, también el uso recreativo. El té de ayahuasca contiene un perfil químico bien característico de compuestos alcaloides psicoactivos que son N, N-dimetiltriptamina (DMT)...
Asian Journal of Psychiatry
June 1, 2024
Adam Włodarczyk, Jakub Słupski, Joanna Szarmach et al.
12 citations
Ketamine is the prototypal rapid-acting antidepressant (RAAD) for TRD with approved indication for esketamine-nasal spray (ESK-NS). Distinctly, arketamine (R-KET) demonstrates enhanced antidepressant effects and neuroplasticity changes compared to esketamine, with fewer dissociative side effects and abuse potential. This study focuses on R-ketamine's therapeutic implications, safety, and...